MoonLake Immunotherapeutics MLTX Return on invested capital

Return on invested capital at other companies

Eli LillyLLY

39.7%+10.3pp

Oruka Therapeutics, Inc.ORKA

-37%—

Shattuck Labs, Inc.STTK

-579.2%-1,580pp

Alumis Inc.ALMS

-155.3%—

Upstream Bio, Inc.UPB

-58.9%—

Kymera TherapeuticsKYMR

-32%-6.7pp

FAQ

What is MoonLake Immunotherapeutics's return on invested capital?

MoonLake Immunotherapeutics (MLTX) reported return on invested capital of -199.6% in Q1 2026.

How has MoonLake Immunotherapeutics's return on invested capital changed year-over-year?

MoonLake Immunotherapeutics's return on invested capital decreased by 75.0% year-over-year, from -114.1% to -199.6%.

What is the long-term trend for MoonLake Immunotherapeutics's return on invested capital?

Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's return on invested capital has grown at a -8.8% compound annual growth rate (CAGR), from -187% to -155.5%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.